# Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

> **NCT00088010** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 9369 (actual)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** Arzoxifene
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00088010
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2009-06
- **Final completion:** 2009-11
- **Target enrollment:** 9369 (ACTUAL)
- **Last updated:** 2010-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088010, "Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00088010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*